Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study
<p>Abstract</p> <p>Background</p> <p>This phase 1b study assessed the maximum tolerated dose (MTD), safety, and pharmacokinetics of motesanib (a small-molecule antagonist of VEGF receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) administered once...
Main Authors: | Sun Yu-Nien, McCoy Sheryl, Siu Lillian L, Welch Stephen, Desai Jayesh, Tebbutt Niall, Kotasek Dusan, Johnson Jessica, Adewoye Adeboye H, Price Timothy |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-07-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/11/313 |
Similar Items
-
Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer
by: Howard Burris, et al.
Published: (2011-01-01) -
Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine
by: Tae Hwan Kim, et al.
Published: (2017-09-01) -
Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors
by: Tasker Andrew S, et al.
Published: (2010-07-01) -
Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience.
by: Michael B Bass, et al.
Published: (2014-01-01) -
Correction: challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience.
by: PLOS ONE Staff
Published: (2015-01-01)